Valuation : Aprea Therapeutics, Inc.

Market Cap 10.56M 9.1M 8.53M 7.79M 14.67M 1.01B 14.72M 101M 39.49M 509M 39.64M 38.78M 1.69B P/E 2026 *
-2.73x
P/E 2027 * -2.97x
Enterprise Value 10.56M 9.1M 8.53M 7.79M 14.67M 1.01B 14.72M 101M 39.49M 509M 39.64M 38.78M 1.69B EV / Sales 2026 *
25.8x
EV / Sales 2027 * 9.33x
Free-Float
83.56%
Yield 2026 *
-
Yield 2027 * -
08-28 Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs CI
08-12 Aprea Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
08-12 Wedbush Adjusts Aprea Therapeutics Price Target to $3 From $6, Maintains Outperform Rating MT
07-30 Aprea Therapeutics, Inc. Provides Update On ACESOT-1051 Program For WEE1 Inhibitor APR-1051 And Expands Clinical Development CI
05-16 Aprea Therapeutics - files for resale of up to 5.5 million shares by selling stockholders - SEC filing RE
05-14 Wedbush Adjusts Price Target on Aprea Therapeutics to $6 From $7, Maintains Outperform Rating MT
05-13 Aprea Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
05-07 Oppenheimer Initiates Aprea Therapeutics at Outperform With $5 Price Target MT
03-31 Aprea Therapeutics, Inc. announced that it has received $30.0204 million in funding from Soleus Capital LLC, Vestal Point Capital, LP, Squadron Capital Management Llc CI
03-30 Aprea Therapeutics, Inc. announced that it expects to receive $30.0204 million in funding from Soleus Capital LLC, Vestal Point Capital, LP, Squadron Capital Management Llc and other investors CI
03-30 Aprea Therapeutics Announces Positive Emerging Clinical Activity for Wee1 Inhibitor Apr-1051 with Confirmed Partial Response in Ongoing Phase 1 Acesot-1051 Trial CI
03-30 Aprea Therapeutics highlights positive emerging clinical activity for WEE1 inhibitor, APR-1051 RE
03-16 Aprea Therapeutics Q4 eps usd -0.32 RE
1 day-2.50%
1 week+30.97%
Current month+35.26%
1 month+36.65%
3 months-9.88%
6 months-8.52%
Current year-1.69%
1 week 0.68
Extreme 0.6801
1.16
1 month 0.59
Extreme 0.5901
1.16
Current year 0.55
Extreme 0.548
1.49
1 year 0.55
Extreme 0.548
1.69
3 years 0.55
Extreme 0.548
8.85
5 years 0.55
Extreme 0.548
25.8
10 years 0.55
Extreme 0.548
25.8
Manager TitleAgeSince
Chief Executive Officer 57 29/06/2022
Director of Finance/CFO 62 30/01/2023
Corporate Officer/Principal 58 01/11/2023
Director TitleAgeSince
Director/Board Member 69 01/01/2015
Director/Board Member 64 01/08/2019
Chairman 63 23/08/2023
Date Insider Type Main position Quantity % Market Cap.
16/06/26 Free

Director

15,690 0.1267%
31/03/26 Buy

Chairman

247,830 2.1642%
31/03/26 Buy

Chief Financial Officer

61,956 0.5410%
Change 5-day change 1-year change 3-year change Capi.($)
-2.50%+30.97%-47.09%-77.03% 10.56M
-1.59%-3.35%+64.49%+98.69% 69.54B
-1.34%-0.75%+48.56%+90.63% 64.97B
-8.37%-12.43%+0.14%-15.42% 25.64B
-2.35%-5.75%-12.17%+448.29% 25.89B
+0.30%-0.69%+63.18%+11.93% 26.51B
-0.96%+10.36%+278.86%+438.78% 20.22B
-0.51%+0.23%+33.71%-18.02% 19.98B
-1.91%-4.37%+13.33%+531.29% 15.69B
-1.47%+0.68%+43.67%+145.49% 13.49B
Average -2.07%+1.36%+48.67%+165.46% 28.19B
Weighted average by Cap. -1.93%-1.50%+57.15%+152.81%

Financials

2026 *2027 *
Net sales 408K 352K 330K 301K 568K 39.04M 569K 3.92M 1.53M 19.71M 1.53M 1.5M 65.35M 1.13M 975K 914K 835K 1.57M 108M 1.58M 10.85M 4.23M 54.59M 4.25M 4.16M 181M
Net income -15.25M -13.14M -12.32M -11.25M -21.18M -1.46B -21.25M -146M -57.02M -736M -57.25M -56M -2.44B -19.24M -16.58M -15.55M -14.19M -26.74M -1.84B -26.82M -184M -71.97M -928M -72.25M -70.68M -3.08B
Net Debt - -
Logo Aprea Therapeutics, Inc.
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality. The Company’s pipeline includes two clinical-stage synthetic lethality programs. Its lead programs are APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small-molecule ATR inhibitor, both in clinical development for solid tumor indications. Its ATRN-119 is an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related (ATR). The ATR kinase is a master regulator of Deoxyribonucleic Acid (DNA) damage response, with roles in cell cycle control and DNA repair following replication stress. It is evaluating potential combination opportunities within its pipeline, including research on the combination of ATRN-119 and APR-1051 that is supported by a Phase II SBIR grant from the National Cancer Institute. It also has an early-stage program, in the lead optimization stage, for an undisclosed DNA-damage response (DDR) target.
Employees
-
Date Price Change Volume
28/08/26 $0.8386 -2.50% 346,178
27/08/26 $0.8601 -12.23% 1,181,958
26/08/26 $0.9800 +3.17% 2,818,694
25/08/26 $0.9499 +17.97% 2,148,901
24/08/26 $0.8052 +25.75% 2,803,206
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.8386USD
Average target price
3.550USD
Spread / Average Target
+323.32%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. APRE Stock